Impact of malignant stem cell burden on therapy outcome in newly diagnosed chronic myeloid leukemia patients

S. Mustjoki, Johan Richter, G. Barbany, Hans Ehrencrona, Thoas Fioretos, T. Gedde-Dahl, B. T. Gjertsen, R. Hovland, S. Hernesniemi, D. Josefsen, P. Koskenvesa, I. Dybedal, B. Markevarn, Tobias Olofsson, U. Olsson-Stromberg, K. Rapakko, S. Thunberg, L. Stenke, B. Simonsson, K. PorkkaH. Hjorth-Hansen

Research output: Contribution to journalArticlepeer-review

49 Citations (SciVal)


Chronic myeloid leukemia (CML) stem cells appear resistant to tyrosine kinase inhibitors (TKIs) in vitro, but their impact and drug sensitivity in vivo has not been systematically assessed. We prospectively analyzed the proportion of Philadelphia chromosome-positive leukemic stem cells (LSCs, Ph+CD34+CD38=) and progenitor cells (LPCs, Ph+CD34+CD38+) from 46 newly diagnosed CML patients both at the diagnosis and during imatinib or dasatinib therapy ( NCT00852566). At diagnosis, the proportion of LSCs varied markedly (1-100%) between individual patients with a significantly lower median value as compared with LPCs (79% vs 96%, respectively, P = 0.0001). The LSC burden correlated with leukocyte count, spleen size, hemoglobin and blast percentage. A low initial LSC percentage was associated with less therapy-related hematological toxicity and superior cytogenetic and molecular responses. After initiation of TKI therapy, the LPCs and LSCs rapidly decreased in both therapy groups, but at 3 months time point the median LPC level was significantly lower in dasatinib group compared with imatinib patients (0.05% vs 0.68%, P = 0.032). These data detail for the first time the prognostic significance of the LSC burden at diagnosis and show that in contrast to in vitro data, TKI therapy rapidly eradicates the majority of LSCs in patients.
Original languageEnglish
Pages (from-to)1520-1526
Issue number7
Publication statusPublished - 2013

Subject classification (UKÄ)

  • Cancer and Oncology


  • CML
  • leukemia stem cell
  • tyrosine kinase inhibitor
  • progenitor


Dive into the research topics of 'Impact of malignant stem cell burden on therapy outcome in newly diagnosed chronic myeloid leukemia patients'. Together they form a unique fingerprint.

Cite this